2019 saw more than 25 acquisition deals being executed in the biotech sector, of which 14 were billion-dollar deals. Bristol-Myers Squibb (BMY) acquiring Celgene for $74 billion in January remains the most expensive acquisition of this year.
from RTT - Biotech https://ift.tt/2PmA2HX
via IFTTT
No comments:
Post a Comment